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Neurobiology of Disease

A Nine Amino Acid Domain Is Essential for Mutant Prion
Protein Toxicity
Laura Westergard,1 Jessie A. Turnbaugh,1,2 and David A. Harris2
1

Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110, and 2Department of Biochemistry,
Boston University School of Medicine, Boston, Massachusetts 02118

Transgenic mice expressing prion protein (PrP) molecules with several different internal deletions display spontaneous neurodegenerative phenotypes that can be dose-dependently suppressed by coexpression of wild-type PrP. Each of these deletions, including the largest
one (⌬32–134), retains 9 aa immediately following the signal peptide cleavage site (residues 23–31; KKRPKPGGW). These residues have
been implicated in several biological functions of PrP, including endocytic trafficking and binding of glycosaminoglycans. We report here
on our experiments to test the role of this domain in the toxicity of deleted forms of PrP. We find that transgenic mice expressing ⌬23–134
PrP display no clinical symptoms or neuropathology, in contrast to mice expressing ⌬32–134 PrP, suggesting that residues 23–31 are
essential for the toxic phenotype. Using a newly developed cell culture assay, we narrow the essential region to amino acids 23–26, and we
show that mutant PrP toxicity is not related to the role of the N-terminal residues in endocytosis or binding to endogenous glycosaminoglycans. However, we find that mutant PrP toxicity is potently inhibited by application of exogenous glycosaminoglycans, suggesting
that the latter molecules block an essential interaction between the N terminus of PrP and a membrane-associated target site. Our results
demonstrate that a short segment containing positively charged amino acids at the N terminus of PrP plays an essential role in mediating
PrP-related neurotoxicity. This finding identifies a protein domain that may serve as a drug target for amelioration of prion neurotoxicity.

Introduction
Transmissible spongiform encephalopathies are progressive neurodegenerative conditions including Creutzfeldt–Jakob disease
in humans and bovine spongiform encephalopathy in cattle
(Prusiner, 2004). These diseases are caused by conformational
conversion of the endogenous cell surface protein, the cellular
isoform of prion protein (PrP C), into an insoluble, ␤-rich isoform, the scrapie isoform of prion protein (PrP Sc), that is selfpropagating and infectious (Prusiner, 1998; Aguzzi and
Polymenidou, 2004). Historically, research in the prion field has
focused on the chemical nature of the infectious agent, with relatively little attention being paid to the mechanism by which
PrP Sc and other abnormal forms of prion protein (PrP) cause
neurodegeneration.
Loss of a normal functional activity of PrP C is unlikely, by
itself, to explain prion neurotoxicity, since mice carrying targeted
deletion of the PrP gene do not display a prion disease phenotype
(Büeler et al., 1992; Manson et al., 1994; Mallucci et al., 2002).
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Nevertheless, several lines of evidence suggest that PrP C plays a
role in neurotoxic signaling pathways that in some way contribute to prion-induced pathology (Harris and True, 2006). For
example, genetic elimination of neuronal PrP C expression in
adult mice greatly prolongs survival and causes reversal of
scrapie-associated neuropathology, despite massive accumulation of PrP Sc (Mallucci et al., 2003, 2007).
Transgenic mice expressing PrP molecules that harbor internal deletions in the unstructured, N-terminal half of the protein
provide potentially important clues to the neurotoxic and neuroprotective signaling mechanisms underlying PrP-associated
neurodegeneration (Solomon et al., 2010a). These deletions,
including ⌬32–121 and ⌬32–134 (Shmerling et al., 1998),
⌬94 –134 (Baumann et al., 2007), and ⌬105–125 (Li et al.,
2007), induce a spontaneous neurological illness characterized by neuronal loss and/or white matter abnormalities. Significantly, the disease phenotype in each of these lines is
suppressed in a dose-dependent fashion by coexpression of
wild-type (WT) PrP, suggesting that WT and mutant molecules physically interact with each other and/or compete for
binding to a common partner.
Interestingly, each of these neurotoxic PrP deletions, including the largest one (⌬32–134), retains 9 aa (residues 23–31,
KKRPKPGGW) immediately following the signal peptide cleavage site. These residues have been implicated in several properties
of PrP C, including endocytic trafficking (Sunyach et al., 2003;
Taylor et al., 2005) and binding of glycosaminoglycans (GAGs)
(Pan et al., 2002; Warner et al., 2002; Taubner et al., 2010). We
therefore wondered whether the 23–31 domain might play some
role in the neurotoxic properties of deleted forms of PrP.
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The present study was undertaken to
investigate this idea using a combination
of transgenic and cell culture approaches.
We report here that removal of residues
23–31 eliminates the toxicity of deleted
forms of PrP in vivo as well as in a cell
culture assay. We also demonstrate that
PrP toxicity is not dependent on endocytosis or binding to endogenous cell surface GAGs, but is potently inhibited by
exogenous GAGs. Our results have
implications for the molecular mechanisms underlying PrP-associated toxicity, and they suggest that the 23–31
region of PrP may represent a novel target for therapeutic intervention in prion
diseases.

Materials and Methods
Plasmid construction. cDNAs encoding murine
⌬23–134 and ⌬32–134 PrPs were generated by
PCR amplification using the following primers:
⌬23–134, 5⬘-GTCCGAAAGCTTCTCGAGGCC
GCCACCATGGCGAACCTTGGCTACTGGCT
GCTGGCCCTCTTTGTGACTATGTGGACTG Figure 1. Schematic of PrP constructs and comparison of sequences in the 23–31 region. A, Schematic of wild-type PrP and
ATGTCGGCCTCTGCAGGCCCATGATCCAT three different deletion constructs. Structural domains of PrP are indicated by the colored blocks: SS (blue), signal sequence; OR
TTTGGC-3⬘ (upstream) and 5⬘-TCGGACTCT (pink), octapeptide repeats; CC (red), charge cluster; HD (green), hydrophobic domain; GPI (purple), GPI attachment signal. The
AGACTCGAGTCATCATCCCACGATCAGGA amino acid sequence of PrP in the 23–31 region is shown above the block diagram; the ⫹ symbols above the sequence indicate
AGAT (downstream); ⌬32–134, 5⬘-TTGTA positively charged amino acids. The dotted lines indicated deleted regions in each construct. B, Consensus alignment for the
CAAGCTTCTCGAGGCCGCCACCATGGCGA conserved region immediately following the signal sequence cleavage site in PrP from different species. Sequences were aligned
ACCTTGGCTACTGG-3⬘ (upstream) and 5⬘- using VectorNTI software. Color coding is as follows: red foreground on yellow background indicates consensus residues that are
TCGGACTCTAGACTCGAGTCATCATCCCA completely conserved in all sequences; blue foreground on cyan background indicates consensus residues derived from a block of
CGATCAGGAAGAT-3⬘ (downstream). WT similar residues at that position; black foreground on green background indicates consensus residues derived from occurrence of
and ⌬105–125 PrP cDNAs were prepared as de- ⬎50% of a single residue at that position; green foreground on white background indicates residues that are weakly similar to the
scribed previously (Li et al., 2007). The upstream consensus residue at that position; black foreground on white background indicates nonsimilar residues. C, Consensus alignment
primers contain HindIII and XhoI restriction for the conserved region immediately following the signal sequence cleavage site in PrP, Doppel, and Shadoo from different
sites, along with a Kozak consensus sequence. species. The color key is the same as in B.
The downstream primers contained XhoI and
XbaI sites. The resulting PCR products were diand P4 primers (Chiesa et al., 1998) were used to amplify the Prn-p⫹
gested with HindIII and XbaI and cloned into pcDNA 3.1 (⫹) Hygro
and Prn-p0 alleles.
Histology. Animals were perfused with 4% paraformaldehyde, after
(Invitrogen).
which brains were isolated and postfixed in the same solution. Paraffin
The QuikChange Site-Directed Mutagenesis kit (Stratagene) was used
sections were stained with hematoxylin and eosin as described previously
to introduce additional mutations into plasmids encoding ⌬105–125 and
(Li et al., 2007).
⌬32–134 PrP. To mutate amino acids 23–27 from KKRPK to KRHPS,
Immunofluorescence localization. BHK, N2a, and HEK cells were maintemplates were subjected to PCR amplification using the following
tained as previously described (Christensen and Harris, 2009). Cells were
primers: 5⬘-GTCGGCCTCTGCAAACGACACCCATCGCCTGGAG
plated on glass coverslips at ⬃50% confluence. The day after plating, cells
GGTGGAACACCG-3⬘ (upstream) and 5⬘-CCGGTGTTCCACwere transfected with Lipofectamine 2000 (Invitrogen) according to the
CCTCCAGGCGATGGGTGTCGTTTGCAGAGGCCGAC-3⬘ (downmanufacturer’s instructions.
stream). To delete residues 23–26, the PCR amplification was
For surface staining, cells were placed on ice for 15 min, washed twice
performed using the following primers: 5⬘-TCGGCCTCTGCAAGCwith
cold PBS, and incubated in PrP antibody 6H4 (Prionics) in OptiCTGGAGGGTGG-3⬘ (upstream) and 5⬘-CCACCCTCCAGGCTTGMEM (Invitrogen). Cells were then washed twice with PBS and fixed for
CAGAGGCCGAC-3⬘ (downstream).
10 min at room temperature in 4% paraformaldehyde in PBS. After washing,
Generation of Tg(⌬23–134) mice. A fragment encoding ⌬23–134 PrP
cells were stained with Alexa Fluor 488 goat anti-mouse IgG (Invitrogen).
was released from the pcDNA3.1 (⫹) Hygro plasmid described above by
For internal staining, cells were fixed as above, permeabilized with
digestion with XhoI and was ligated into XhoI-digested expression vector
0.2% Triton X-100 for 5 min at room temperature, and then stained with
MoPrP.Xho (Borchelt et al., 1996). The transgene was released from the
antibody 6H4 along with rabbit polyclonal antibodies for the Golgi
recombinant plasmid by NotI restriction digest and purified on GFX
marker, giantin (Covance), or the ER marker, TRAP (Millipore). Cells
PCR DNA purification columns (GE Healthcare). The purified DNA was
were then stained with Alexa Fluor 488 goat anti-mouse IgG and Alexa
then injected into the pronuclei of fertilized eggs from C57BL/6J ⫻ CBA
Fluor 594 goat anti-rabbit secondary antibodies (Invitrogen).
F1 hybrid mice. Transgenic founders were bred initially to Tga20 ⫹/⫹
After staining, coverslips were mounted on glass slides and viewed in
0/0
mice and then to Zurich I Prn-p mice on a pure C57BL/6 background
Nikon TE-2000E inverted fluorescence microscope. Images captured
(EMMA). Genotyping of transgenic mice was performed by PCR analysis
with MetaMorph software (Molecular Devices).
of tail DNA prepared using the Puregene DNA Isolation kit (Gentra
Endocytosis assays. N2a cells were plated on glass coverslips 1 d before
Systems). Primers P1 and P4 (Chiesa et al., 1998) were used for genotransfection with Lipofectamine 2000 according to the manufacturer’s
typing. These primers will amplify both ⌬23–134 PrP and Tga20
instructions. Cells were removed from incubator, placed on ice for 15
transgenes, which can be distinguished from each other by size. P2
min, and then surface-labeled on ice with PrP antibody 6H4 in Opti-
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Figure 2. Analysis of PrP expression in Tg(⌬23–134) mice. A, Brain homogenates containing equal amounts of total protein from mice expressing the indicated forms of PrP were either untreated
(⫺ symbols) or were treated with PNGase F to remove N-linked oligosaccharides (⫹ symbols). Samples were then subjected to Western blotting with anti-PrP antibody 6H4. The arrowhead points to the C1
cleavage product of full-length PrP (Chen et al., 1995) in lane 2. B, Brain homogenates containing equal amounts of total protein from mice expressing the indicated forms of PrP were subjected to Western
blotting with the indicated anti-PrP antibodies. The schematic below the blot indicates the locations of the epitopes recognized by each of the antibodies. Molecular size markers are given in kilodaltons.
MEM. Cells were then returned to 37°C for 60 min to induce PrP internalization. Next, cells were washed twice with PBS, treated with 0.5%
trypsin/0.2% EDTA on ice to remove surface proteins, and fixed for 10
min at room temperature in 4% paraformaldehyde in PBS. Fixative was
removed and cells were washed with PBS. Cells were permeabilized with
0.2% Triton X-100 for 5 min at room temperature, blocked for 1 h in 2%
goat serum in PBS, and stained with fluorescently conjugated secondary
antibodies in goat serum/PBS for 1 h. Finally, coverslips were mounted
on glass slides and visualized by fluorescent microscopy as described
above.
HEK cells stably expressing WT and mutant PrPs were plated on glass
coverslips. The following day, cells were placed on ice for 10 min, and surface
PrP was labeled with PrP antibody 6H4 in Opti-MEM on ice for 15 min.
Cells were then washed, warm medium was added, and cells were incubated
at 37°C for 30 min to allow endocytosis to occur. At the end of this period,
cells were fixed without permeabilization as described above. All cells were
labeled with Alexa 488-coupled anti-mouse IgG (Invitrogen). Coverslips
were then mounted on glass slides and visualized as described above.
Western blotting and PrP insolubility assay. Brain homogenates (10%
w/v) were prepared by mechanical dissociation of single hemispheres using
plastic pestles (South Jersey Precision Tool and Mold) in PBS containing
Protease Inhibitor Cocktail Tablet (Roche). The suspension was clarified for
5 min at 2300 ⫻ g in a microcentrifuge. Total protein in the supernatant was

quantitated using the BCA kit (Pierce). After separation by SDS-PAGE, proteins were transferred to PVDF membranes (Millipore) and probed overnight with PrP antibodies (6H4, 6D11, 32.1.1, or P45-66) in 5%
nonfat milk, washed with TBS/0.1% Tween, and incubated in HRPconjugated secondary antibodies (Sigma-Aldrich; or Pierce). Blots
were developed with ECL detection system (GE Healthcare).
Detergent-resistant membrane localization. Isolation of detergent-resistant
membranes was conducted as previously described (Christensen and Harris,
2009). Briefly, HEK cells stably expressing WT or mutant ⌬23–134 PrPs were
lysed in 25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, and 1% Triton
X-100, on ice. Lysates were mixed with a 60% OptiPrep solution (SigmaAldrich) to achieve at final concentration of 40% OptiPrep. An OptiPrep
gradient ranging from 0% (top) to 30% (bottom) was layered atop the lysate/
OptiPrep mixture. After 4°C ultracentrifugation for 4 h at 172,000 ⫻ g, a 200
l aliquot of each gradient fraction was methanol precipitated and analyzed
by Western blotting with anti-PrP antibody (6H4) and anti-flotillin antibody (BD Biosciences).
Cell culture assays for mutant PrP toxicity. Cell viability and H2AX
phosphorylation assays were performed as described previously (Massignan et al., 2010). In the first assay, HEK cells stably expressing WT or
mutant PrPs were treated with Zeocin (500 g/ml) or (2 R,3S,4 R,5R,6S)5-amino-6-[(1 R,2S,3S,4 R,6S)-4,6-diamino-3-[(2 R,3R,4 R,5R)-3,5dihydroxy-5-methyl-4-methylamino-oxan-2-yl]oxy-2-hydroxycyclohexyl]
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oxy-2-(1-hydroxyethyl)oxane-3,4-diol (G418)
(400 g/ml) for 48 h, after which cell viability
was assayed by MTT reduction. In the second
assay, HEK cells were treated for 30 min with
Zeocin, after which cells were lysed, and phosphorylated H2AX analyzed by Western blotting using the Odyssey fluorescent imaging
system (LI-COR). Actin levels were analyzed as
a loading control.
GAG experiments. To test the effect of exogenous GAGs on mutant PrP toxicity, heparin
(100 g/ml) (Sigma-Aldrich) or pentosan sulfate (100 g/ml) were included during incubation with G418 or Zeocin. Three different
molecular size forms of PS were tested: 3000 Da
(Sigma-Aldrich); 4500 or 5000 Da (both from
Biopharm). Cell viability or phosphorylated
Figure 3. Tg(⌬23–134) mice remain healthy, while Tg(F35) mice develop a fatal neurological illness. The plot shows the
H2AX was then measured as described above.
genotypes remaining alive at each age. The number of mice, of either sex, in each group was
To test the role of endogenous GAGs, cells percentage of mice of the indicated
0/0
, 12 for Tg(⌬23–134L)/Prn-p0/0, 14 for Tg(F35)/Prn-p0/0, 7 for Tg(F35)/Prn-p⫹/0, 6 for Prn-p0/0,
were either pretreated for 1 h with 5 mU/ml 12 for Tg(⌬23–134H)/Prn-p
⫹/0
heparinase II (Sigma-Aldrich) or were incu- and 7 for Prn-p .
bated for 24 h with 30 mM sodium chlorate in
expression level comparable with that of Tg(F35) mice expressing
Opti-MEM before addition of Zeocin. Cell viability or phosphorylated
⌬32–134 PrP (Shmerling et al., 1998). On Western blots, the
H2AX were then measured as described above.
To measure the effect of chlorate on GAG sulfation, cells were
majority of ⌬23–134 protein migrates as a single species of ⬃30
pretreated with 30 mM sodium chlorate in Opti-MEM for 24 h, after
kDa. After enzymatic removal of the N-linked oligosaccharides
which 25 Ci/ml 35SO4 (PerkinElmer) was added, and cells were
using PNGase F, the protein migrates as a single band of the
incubated for an additional 48 h. Cells were then lysed, and radioacexpected size (⬃16 kDa), slightly faster than the endogenous C1
tive counts in cell lysates were measured in a scintillation counter.
fragment, which is missing residues 23–111 (Chen et al., 1995).
To measure the effect of heparinase digestion on cell surface GAGs,
Thus, similar to ⌬32–134 PrP (Shmerling et al., 1998), the ⌬23–
35
cells were incubated for 48 h in Opti-MEM containing 25 Ci/ml SO4,
134 protein exists primarily in a glycosylated form. Western blot
after which the labeling medium was removed and cells were incubated
analysis with a panel of PrP-specific antibodies demonstrates
for 30 min in fresh medium containing heparinase II. Cells were then
that, as expected, ⌬23–134 PrP is recognized by a C-terminal
lysed, and radioactivity in cell lysates was measured in a scintillation
specific antibody (6H4, residues 144 –152), but not N-terminally
counter.

Results

Construction of transgenic mice expressing ⌬23–134 PrP
Tg(F35) mice expressing PrP deleted for residues 32–134 exhibit
cerebellar ataxia and neurodegeneration, and succumb to illness
by 100 d in the absence of full-length PrP (Shmerling et al., 1998).
The ⌬32–134 deletion preserves residues 23–31 (KKRPKPGGW)
immediately following the signal sequence cleavage site (Fig. 1 A).
This region, which includes a cluster of four positively charged
residues, is highly conserved in PrP from several mammalian
species (Fig. 1 B). Multiple positively charged residues are also
present in the region following the signal peptide cleavage site in
nonmammalian PrPs and in the PrP paralogs, Doppel and Shadoo (Fig. 1 B, C).
To investigate the role of residues 23–31 in the neurotoxicity
of ⌬32–134 PrP, we generated transgenic mice expressing ⌬23–
134 PrP under control of a modified version of the endogenous
Prn-p promoter. ⌬23–134 represents a further deletion that abolishes the entire N terminus of PrP, including residues 23–31 (Fig.
1 A). Seven transgene positive founders were recovered. In case
⌬23–134 PrP proved to be highly toxic in the absence of WT PrP,
we first bred Tg(⌬23–134) founders to Tga20 ⫹/⫹ mice (Fischer et
al., 1996) that overexpress WT PrP. Tg(⌬23–134)/Tga20 ⫹/0
progeny were subsequently bred to Prn-p0/0 mice on the C57BL/6
background to obtain Tg(⌬23–134)/Prn-p0/0 offspring lacking
endogenous or transgenically encoded WT PrP.
Two Tg(⌬23–134) lines, designated H (high) and L (low),
were found to be positive for transgene expression by RT-PCR
(data not shown) and Western blotting (Fig. 2 A). The H and L
lines express ⌬23–134 PrP at ⬃2 and 0.5 times the level of endogenous PrP, respectively. Thus, the Tg(⌬23–134H) line has a PrP

directed antibodies (M32.1.1, residues 23–50; P45-66, residues
45– 66; 6D11, residues 95–100) (Fig. 2 B).
Tg(⌬23–134) mice show no clinical illness or histopathology
Both the H and L lines of Tg(⌬23–134) mice on the Prn-p0/0
background remained clinically normal for ⬎400 d (Fig. 3). Conversely, 100% of Tg(F35) mice on the Prn-p0/0 background exhibited tremor and ataxia by 32 d, which progressed to a total
hindlimb paralysis and finally death by 100 d (Fig. 3). In addition, Tg(⌬23–134)/Prn-p0/0 mice of both lines demonstrated no histopathological abnormalities for at least 1 year
(as long as they were observed) (Fig. 4) (data not shown). In
contrast, Tg(F35)/Prn-p0/0 mice showed significant degeneration of cerebellar granule neurons by 10 weeks of age (Fig. 4).
We conclude that ⌬23–134 PrP, in contrast to ⌬32–134 PrP
expressed at an equivalent level, does not cause significant
neurotoxicity in transgenic mice.
Cellular localization and biochemical properties of ⌬23–134
PrP in cultured cells
We tested whether the lack of toxicity of ⌬23–134 PrP was attributable to an alteration in its cellular localization compared with
⌬32–134 PrP. In transfected BHK cells, ⌬23–134 PrP, like WT
and ⌬32–134 PrPs, was localized to the cell surface when assayed
by immunostaining of intact cells with PrP antibody 6H4 (Fig.
5A–C). Furthermore, the ⌬23–134 protein, like the WT and ⌬32–
134 proteins, was attached to the cell surface by a glycosylphosphatidylinositol (GPI) anchor, as demonstrated by its release
after treatment of cells with phosphatidylinositol-specific phospholipase C (PIPLC), a bacterial enzyme that cleaves the GPI
anchor (Fig. 5D–F ). After PIPLC treatment, both ⌬23–134 and
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Additionally, when ⌬23–134 PrP was
analyzed by density gradient flotation, we
found that, like WT PrP, ⌬23–134 PrP
was distributed in fractions that contained
the lipid raft resident protein flotillin-1
(data not shown).
In conclusion, our analyses reveal that
⌬23–134 PrP has a cellular localization
and solubility similar to those of WT and
⌬32–134 PrPs.

Figure 4. Tg(⌬23–134) mice display normal cerebellar histology, while Tg(F35) mice show cerebellar atrophy and massive loss
of granule neurons. A–D show hematoxylin/eosin-stained cerebellar sections from 70-d-old mice of either sex of the indicated
genotypes. The area outlined by the box in each panel is shown at higher magnification in E–H. Scale bars: (in A) A–D, 1 mm; (in
E) E–H, 50 m.

WT PrPs were detected in the cell culture medium by Western
blotting of methanol-precipitated proteins (data not shown). Intracellularly, ⌬23–134 PrP colocalized with the Golgi marker,
giantin, in BHK cells, demonstrating trafficking through the secretory pathway, similar to WT and ⌬32–134 PrPs (Fig. 5G–I ).
Similar results were obtained when localization and biochemical
analyses were performed on ⌬23–134 PrP expressed in transfected HEK and N2a cells (data not shown), as well as in cerebellar granule neurons cultured from Tg(⌬23–134) mice (Fig. 5J–M).
After ultracentrifugation at 265,000 ⫻ g, ⌬23–134 PrP in detergent lysates of transfected BHK cells was found in the supernatant fraction, similar to WT PrP and in contrast to PG14 PrP,
an aggregation-prone mutant PrP (data not shown).

⌬23–134 PrP is not toxic in a cell
culture assay
We previously reported a cell culture assay
for the toxicity of certain mutant forms of
PrP, including ⌬32–134 and ⌬105–125
(Massignan et al., 2010). The assay is
based on the ability of these mutant PrP
molecules to render cells hypersensitive to
several cationic drugs, including G418,
hygromycin, and Zeocin. The assay mimics several essential features of PrP toxicity
seen in transgenic mice, including rescue
by coexpression of wild-type PrP.
We assayed the toxic activity of ⌬23–
134 PrP and compared it with the activity
of ⌬32–134 and ⌬105–125 PrPs. Stably
transfected HEK cells expressing these
mutant PrP molecules were incubated for
48 h in the presence of 400 g/ml G418,
and cell viability was assayed by enzymatic
reduction of the MTT reagent. As reported
previously (Massignan et al., 2010), we
found that cells expressing ⌬32–134 or
⌬105–125 PrP showed significantly reduced viability compared with control
cells expressing WT PrP or empty vector,
with ⌬105–125 being more potent than
⌬32–134, reflective of the relative toxicities of these two molecules in transgenic
mice (Fig. 6). In contrast, HEK cells expressing ⌬23–134 did not show altered viability in this assay. Similar results were
obtained for several clones expressing
each construct at equivalent levels as determined by Western blotting (data not
shown). These results demonstrate that the
lack of toxicity of ⌬23–134 in transgenic
mice is reflected in a cell culture assay.

Mutant PrP toxicity is not correlated with endocytosis
The discrepancy between the toxic activities of ⌬32–134 and ⌬23–
134 PrPs in both in vivo and in vitro settings suggests that residues
23–31 may represent an important toxicity-determining region.
This positively charged region has been previously implicated in
several properties of PrP, one of which is endocytic trafficking and
targeting to clathrin-coated pits (Nunziante et al., 2003; Sunyach et
al., 2003; Taylor et al., 2005). We therefore investigated whether
endocytosis was necessary for the toxicity of deleted forms of PrP.
We used two complementary assays to measure the endocytosis of WT, ⌬23–134, ⌬32–134, and ⌬105–125 PrPs. Our initial
experiments used transiently transfected N2a neuroblastoma
cells, which were previously shown to exhibit significant consti-
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tutive endocytosis of PrP C (Shyng et al.,
1993, 1995a). After immunolabeling surface PrP at 4°C, cells were incubated at
37°C to initiate endocytosis. After 1 h,
cells were treated with trypsin to remove
residual surface PrP and were then fixed,
permeabilized, and incubated with a fluorescently conjugated secondary antibody
to selectively visualize internalized PrP.
Cells expressing all constructs that were
immunolabeled at 4°C but not warmed to
37°C demonstrated strong labeling of the
cell surface, reflective of the initial distribution of the PrP before endocytosis (Fig.
7A–D). After incubation at 37°C, both
WT and ⌬105–125 PrPs exhibited punctate intracellular fluorescence staining
corresponding to endosomal compartments to which antibody-labeled PrP had
been delivered (Fig. 7 E, H ). In marked
contrast, ⌬23–134 and ⌬32–134 PrPs
were not significantly endocytosed, since
no antibody-labeled PrP appeared inside
the cells (Fig. 7 F, G).
We confirmed these results in another
cell type using a second kind of assay to
measure PrP endocytosis. In this experiment, using stably transfected HEK cells,
internalization of PrP was scored by observing the loss of antibody-bound PrP
from the cell surface. Cells were labeled at
4°C with antibody 6H4 and were then incubated at 37°C to initiate endocytosis.
Subsequently, cells were fixed without permeabilization and PrP remaining on the cell
surface was visualized by incubation with a
fluorescently labeled secondary antibody. In
control cells that were not warmed to 37°C,
surface staining for PrP was, as expected,
observed for each of the constructs (Fig.
7I–L). After incubation at 37°C, surface
staining remained visible for ⌬23–134 and
⌬32–134 PrPs (Fig. 7N,O), but not for WT
or ⌬105–125 PrPs (Fig. 7M,P), reflecting
impaired endocytosis of the two former
mutants, and paralleling the results ob- Figure 5. ⌬23–134 PrP traffics through the Golgi apparatus and is GPI-anchored to the cell surface. A–I, BHK cells were
transiently transfected with plasmids encoding the indicated forms of PrP, along with a plasmid encoding DsRed (A–F) targeted to
tained using the other assay in N2a cells.
the ER (to mark transfected cells). A–F, Cells were incubated either with (D–F ) or without (A–C) PIPLC to cleave GPI-anchored cell
Since neither ⌬32–134 nor ⌬23–134 surface proteins and were then stained live on ice with anti-PrP antibody 6H4. Cells were then fixed without permeabilization and
PrP were efficiently endocytosed, we con- stained with fluorescently tagged secondary antibody to reveal PrP. Nuclei were visualized by staining with DAPI. The panels show
clude that the lack of toxicity of the latter merged green (PrP), red (Ds-Red ER), and blue (DAPI) images. G–I, Fixed and permeabilized cells were stained with anti-PrP
mutant cannot be attributed to its im- antibody 6H4 (green), along with an antibody to the Golgi marker, giantin (red), and DAPI (blue). J–M, Cerebellar granule neurons
paired endocytosis. In addition, ⌬105– were isolated from either wild-type mice (J, L) or Tg(⌬23–134) mice (K, M ). Cells were stained for PrP (green) either without
125 PrP, which elicits a neurodegenerative permeabilization (J, K ), or after fixation, permeabilization, and costaining for giantin (red) (L, M ). Cell nuclei were stained with
phenotype like ⌬32–134 PrP (Li et al., DAPI (blue). Scale bars: (in I ) A–I, 25 m; (in M ) J–M, 40 m.
2007), is constitutively endocytosed. Toin the 23–31 region that have been shown previously to abolish engether, these results demonstrate a lack of correlation between
docytosis of WT PrP: the triple mutation K24R/R25H/K27S [similar
mutant PrP neurotoxicity and endocytic trafficking.
to that in the study by Sunyach et al. (2003)] and deletion ⌬23–26
23
26
(Taylor et al., 2005). As expected, both of these alterations abolished
Lys -Pro are necessary for the toxicity of ⌬105–125 and
endocytosis of ⌬105–125 PrP as assayed by loss of surface staining
⌬32–134 PrPs
for PrP in HEK cells (Fig. 8A–F) and quantified in Figure 8G.
To further examine the connection between PrP toxicity and endoWe next tested how these alterations in the 23–31 region afcytosis, we performed mutagenesis of the 23–31 region of ⌬105–125
PrP. We constructed two versions of ⌬105–125 PrP with alterations
fected the toxicity of ⌬105–125 PrP as measured by the drug
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Figure 6. ⌬23–134 PrP is not toxic in a cell culture assay. HEK cells stably expressing the
indicated constructs were treated for 48 h in the presence or absence of 400 g/ml G418, after
which cell viability was measured by MTT reduction. Cell viability is expressed as the value for
MTT reduction (A570) of G418-treated cells as a percentage of the value for untreated cells. The
bars show mean values ⫾ SEM. The asterisks indicate values that are significantly different
from those for WT PrP (p ⬍ 0.0001).

hypersensitivity assay. Interestingly, introduction of the K24R/
R25H/K27S triple mutation had no effect on the toxicity of
⌬105–125 PrP, whereas the ⌬23–26 deletion rendered ⌬105–125
PrP nontoxic (Fig. 8H). A similar phenomenon was observed
when these two alterations were introduced into the ⌬32–134 PrP
molecule (Fig. 8H). Together, these results demonstrate that the
toxicity of ⌬105–125 and ⌬32–134 PrPs is independent of endocytosis, but requires the presence of 4 aa (Lys 23-Pro 26) at the N
terminus.
Mutant PrP toxicity is abrogated by exogenous GAGs
Another well documented functional activity of the N-terminal
region of PrP is binding to GAGs. Residues 23–35 have been
shown to constitute one of several GAG binding sites in PrP (Pan
et al., 2002; Warner et al., 2002; Taubner et al., 2010), and there is
evidence that binding of GAGs alters several activities of PrP C,
including its endocytic trafficking (Shyng et al., 1995b) and its
conversion to PrP Sc (Caughey and Raymond, 1993). We therefore investigated the role of GAG binding in the toxicity of mutant PrP using in vitro assays.
To explore the role of GAG binding in the toxicity of ⌬32–134
and ⌬105–125 PrPs, we tested the effect of heparin and pentosan
sulfate (PS), two GAGs known to bind PrP C, in the drug hypersensitivity assay. We found that addition of both compounds to
HEK cells expressing ⌬105–125 PrP significantly diminished cell
death in the presence of G418 (Fig. 9A) or Zeocin (data not
shown) when assayed by MTT reduction. Pentosan sulfate had a
more potent effect than heparin, corresponding to the higher
affinity of the former for PrP C (Brimacombe et al., 1999). The
rescuing effect of PS was seen with both low- and highmolecular-weight forms of PS, indicating that the effect was not
dependent on the size of the molecule (data not shown). As an
additional control, we treated untransfected HEK cells with heparin in the presence of G418 and did not observe any effect on cell
viability even at very high concentrations of G418 that were sufficient to kill a significant proportion of the cells (data not
shown). This result demonstrated that suppression of ⌬105–125
toxicity by heparin is not due to an overall increase in cell viability, or inhibition of the action of G418. We observed a similar
rescuing effect of heparin and PS from the toxicity of ⌬32–134
PrP in the HEK cell viability assay with G418 (data not shown).
To confirm these results using another assay, we tested the
effect of heparin and PS on Zeocin-induced phosphorylation of
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histone H2AX in cells expressing ⌬105–125 PrP. H2AX is a variant histone that is rapidly phosphorylated in response to doublestrand breaks in DNA induced by genotoxic agents like Zeocin.
We showed previously that HEK cells expressing ⌬105–125 PrP
exhibit enhanced phosphorylation of H2AX after treatment with
Zeocin (Massignan et al., 2010), presumably reflecting increased
entry of Zeocin into the cells. We observed here that both heparin
and PS suppressed this Zeocin-induced increase in H2AX phosphorylation (Fig. 9 B, C), consistent with the ability of these compounds to suppress Zeocin-induced cell death as measured by
MTT reduction (data not shown). Again, PS was more potent
than heparin.
Since GAGs have been shown to induce endocytosis of PrP
(Shyng et al., 1995b), we tested the possibility that the suppressive effect of these compounds on mutant PrP toxicity was
due to removal of PrP from the cell surface. PrP internalization was analyzed as described above, based on loss of surface
staining for PrP. We found that treatment with PS or heparin
at concentrations that suppressed ⌬105–125 and ⌬32–134
toxicity induced internalization of WT and ⌬105–125 PrP, but
not ⌬32–134 PrP (data not shown). These results demonstrate
that heparin and PS are likely to be rescuing mutant PrP toxicity by a mechanism that does not depend on internalization
of PrP from the cell surface.
Mutant PrP toxicity is not dependent on endogenous GAGs
Given our observation that exogenous GAGs are capable of inhibiting the toxicity of mutant PrPs, we wondered whether endogenous, cell-derived GAGs might be required as part of the
mechanism by which mutant PrPs exert their toxic activity. We
therefore analyzed the effect of interfering with the synthesis of
endogenous GAG chains, and of cleaving these chains enzymatically, on the toxicity of ⌬105–125 PrP in the HEK cell drug
hypersensitivity assay.
Chlorate inhibits GAG chain sulfation by acting as a competitive inhibitor of ATP-sulfurylase (Baeuerle and Huttner,
1986). We pretreated HEK cells expressing ⌬105–125 PrP for
24 h with sodium chlorate, and then analyzed H2AX phosphorylation in response to Zeocin exposure. We observed that
chlorate treatment had no significant effect on the level of
H2AX phosphorylation (Fig. 10). To confirm that chlorate
treatment was inhibiting GAG sulfation, we quantitated cellular incorporation of 35SO4. We found that incubation with
chlorate reduced 35SO4 incorporation to ⬃60% of the levels in
untreated cells (data not shown). The residual level of cellassociated radioactivity after chlorate treatment most likely
represents 35SO4 incorporation into other intracellular sulfated proteins and amino acids (data not shown).
We also investigated the effect on ⌬105–125 PrP toxicity of
enzymatically digesting cell surface GAG chains using heparinase II. This enzyme cleaves heparan sulfate chains at the one
to four linkages between hexosamines and uronic acid residues. We pretreated HEK cells expressing ⌬105–125 PrP for 30
min with heparinase II and then analyzed Zeocin-induced
phosphorylation of H2AX. We found that heparinase II treatment had no effect on phosphorylated H2AX levels (Fig. 11).
To confirm that heparinase II had cleaved cell surface GAG
chains, we monitored release of radioactivity from cells that
had been previously labeled with 35SO4. We found that cellassociated radioactivity decreased by ⬃40% after heparinase
II treatment for both wild-type (data not shown) and ⌬105–
125 PrPs (data not shown), similar to the reduction produced
by treatment with chlorate.
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Together, these results indicate that
cell surface heparan sulfate chains and sulfation of endogenous GAG chains are not
necessary for the toxicity of ⌬105–125 PrP
in an in vitro assay.

Discussion
Several deletions in the N-terminal tail of
PrP induce spontaneous neurodegeneration in transgenic mice (Shmerling et al.,
1998; Baumann et al., 2007; Li et al., 2007)
and display toxic activity in a cell culture
assay (Massignan et al., 2010). Each of
these deletions, including the largest one
(⌬32–134), retains a highly conserved
segment of 9 aa immediately following the
signal peptide cleavage site (residues 23–
31; KKRPKPGGW). This study was undertaken to investigate the role of residues
23–31 in the toxic activity of deleted forms
of PrP. Our results demonstrate that these
residues are essential for toxicity in both
transgenic mice and cell culture. The
contribution of these residues does not
depend on their role in endocytic trafficking or binding of endogenous GAGs.
However, we have discovered that addition of exogenous GAG molecules can
dramatically suppress the toxicity of deleted PrP forms. These results suggest
possible mechanisms underlying PrP
toxicity, and they implicate the 23–31
region as a possible therapeutic target in
treatment of prion diseases.
Importance of residues 23–31
We report here that, in contrast to
Tg(F35) mice expressing ⌬32–134 PrP,
which develop a spontaneous neurodegenerative illness within 3 weeks of birth,
Tg(⌬23–134) mice remain healthy and Figure 7. ⌬105–125 PrP, but not ⌬23–134 or ⌬32–134 PrPs, are endocytosed in N2a and HEK cells. A–H, Living N2a cells
free of neuropathology for ⬎1 year. Both expressing the indicated constructs were surface-labeled for PrP at 4°C. One set of cultures (A–D) was immediately fixed and
stained with fluorescent secondary antibody to confirm the initial distribution of surface PrP. The other set of cultures (E–H ) was
kinds of mice express the transgene at
warmed to 37°C for 1 h to allow endocytosis to occur, after which surface PrP was removed with trypsin, and then the cells were
comparable levels under control of the fixed, permeabilized, and stained with fluorescent secondary antibody to reveal the distribution of internalized PrP. Accumulations
identical, modified PrP promoter. Since of PrP in endocytic structures are visible in E and H, but not in F and G. I–P, Living HEK cells expressing the indicated constructs were
the only difference between the proteins surface labeled for PrP at 4°C. One set of cultures (I–L) was immediately fixed and stained with fluorescent secondary antibody to
encoded by these two transgenes is the confirm the initial distribution of surface PrP. The other set of cultures (M–P) was warmed to 37°C for 1 h to allow endocytosis to
presence (in ⌬32–134) or absence (in occur, after which cells were stained with fluorescent secondary antibody without permeabilization to reveal the amount of PrP
⌬23–134) of residues 23–31, our results remaining on the surface. Loss of surface PrP, indicative of endocytosis, is evident in M and P, but not in N and O. Scale bar: (in P)
strongly implicate 23–31 as an essential A–P, 50 m. Quantification of PrP endocytosis using ImageJ software was performed by measuring the average pixel intensity of
neurotoxicity-determining region. These PrP immunofluorescence inside the cell (Q) or on the cell surface (R) after warming to 37°C compared with the initial surface
in vivo results were confirmed by a new immunofluorescence. PrP signals were normalized to fluorescence signal for DAPI, as a measure of cell number. The bars show
cell culture assay we developed based on mean values ⫾ SEM. The asterisks indicate values that are significantly different from those for WT PrP (p ⬍ 0.001).
hypersensitivity to the toxic effects of sevdiminished ability to suppress the neurodegenerative phenotype
eral cationic drugs (Massignan et al., 2010). This assay demonof mice coexpressing ⌬32–134 PrP (J.A. Turnbaugh, L. Westerstrates that the removal of as few as 4 aa from the N-terminal
gard, D.A. Harris, unpublished observations).
region (Lys 23-Pro 26) is sufficient to abrogate the toxicity of ⌬32–
How might the 23–31 region play a role in the toxic activity of
134 and ⌬105–125 PrPs.
deleted forms of PrP? These nine residues have been implicated
Interestingly, there is evidence that the 23–31 region may also
previously in several biological functions of PrP C, including the
be essential for the ability of wild-type PrP to protect cells against
following: endocytic trafficking and localization to clathrinthe toxic effects of deleted forms of PrP or Doppel (Atarashi et al.,
coated pits (Sunyach et al., 2003; Taylor et al., 2005), binding of
2003; Drisaldi et al., 2004; Yoshikawa et al., 2008). In this regard,
GAGs (Pan et al., 2002; Warner et al., 2002; Taubner et al., 2010),
we have found that ⌬23–134 and ⌬23–31 PrPs display greatly
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surface (Shyng et al., 1993, 1994). Previous studies indicated that the N-terminal
region of PrP C, including residues 23–31,
plays an important role in targeting the
protein to clathrin-coated pits and promoting its subsequent endocytosis. Deletion of Lys 23-Pro 26 (Taylor et al., 2005) or
mutation of three of the four positively
charged residues (Sunyach et al., 2003)
has been shown to significantly impair
endocytosis of mammalian PrP C. In addition, several N-terminal deletions reduce
endocytosis of chicken PrP C (Shyng et al.,
1995a).
Our results indicate that endocytosis is
not required for the toxicity of deleted
forms of PrP. Neither ⌬23–134 nor ⌬32–
134 PrP were endocytosed, yet the latter
mutant was toxic in our in vitro assay and
in transgenic mice. Moreover, the triple
mutation K24R/R25H/K27S abolished
endocytosis of ⌬105–125 PrP but had no
effect on its toxicity. Thus, we conclude
that the lack of toxicity of ⌬23–134 PrP
both in transgenic mice and in cell culture
is not caused by impaired endocytosis.
Exogenous GAGs inhibit mutant PrP
toxicity, but endogenous GAGs are not
required for toxicity
Previous studies have identified GAG
binding sites in PrP using recombinant
protein and synthetic peptides. Three regions of PrP were identified as sufficient
for binding of heparin and heparan sulfate
(HS), including residues 23–52, 53–93,
Figure 8. Residues 23–26 are essential for the endocytosis and toxicity of ⌬32–134 and ⌬105–125 PrPs. Transfected HEK cells and 110 –128 (Pan et al., 2002; Warner et
expressing the indicated constructs were surface labeled for PrP at 4°C. (KRHPS indicates the triple mutation K24R/R25H/K27S.) al., 2002). The first region contains the seOne set of cultures (A–C) was immediately fixed and stained with fluorescent secondary antibody to confirm the initial distribution quence KKRPKP (residues 23–28), which
of surface PrP. The other set of cultures (D–F ) was warmed to 37°C for 1 h to allow endocytosis to occur, after which cells were is similar to a previously identified HS
stained with fluorescent secondary antibody without permeabilization to reveal the amount of PrP remaining on the surface. Loss binding consensus sequence XBBBXXBX,
of surface PrP, indicative of endocytosis, is evident in D, but not in E and F. Scale bar: (in F ) A–F, 50 m. G, Quantification of PrP where B is a basic residue and X is an unendocytosis using ImageJ software was performed by measuring the average pixel intensity of PrP immunofluorescence on the cell charged or hydrophobic residue (Cardin
surface after warming to 37°C compared with the initial surface immunofluorescence. PrP signals were normalized to fluorescence and Weintraub, 1989). There is evidence
signal for DAPI, as a measure of cell number. The bars show mean values ⫾ SEM. The asterisks indicate values that are significantly
that the GAG-binding domains of PrP
different from those for WT PrP (p ⬍ 0.001). H, HEK cells expressing the indicated constructs were treated for 48 h in the presence
may interact with glypican-1, an endogor absence of 400 g/ml G418, after which cell viability was measured by MTT reduction. (KRHPS indicates the triple mutation
K24R/R25H/K27S.) Cell viability is expressed as the value for MTT reduction (A570) of G418-treated cells as a percentage of the value enous heparan sulfate proteoglycan that
C
for untreated cells. The bars show mean values ⫾ SEM. The asterisks indicate values that are significantly different from those for mediates lipid raft association of PrP
(Taylor et al., 2009). Moreover, exogeWT PrP (p ⬍ 0.0001).
nous GAGs stimulate endocytosis of
nuclear localization (Gu et al., 2003), retrograde axonal transport
PrP C (Shyng et al., 1995b). In addition to their interaction
with PrP C, GAGs have also been shown to inhibit formation of
(Hachiya et al., 2004a,b), antimicrobial activity (Pasupuleti et al.,
PrP Sc, and to delay disease in animal models (Caughey and
2009), binding of the Alzheimer’s A␤ peptide (Chen et al., 2010),
Raymond, 1993; Doh-ura et al., 2004).
regulation of ␤-secretase activity (Parkin et al., 2007), and transduction of polypeptide segments across the lipid bilayer (Wadia et al.,
Our data demonstrate that two GAGs, heparin and PS, when
2008). Of these putative functions, the most extensively characterapplied exogenously, significantly suppress the toxicity elicited
ized are endocytic trafficking and GAG binding. The relationship
by PrP mutants in our cell culture assay. The strength of this effect
between these two functions and the toxicity of PrP mutants was
correlates with the binding affinity of these molecules for PrP
(Brimacombe et al., 1999), with PS being more potent than heptherefore the focus of the studies reported here.
arin. In contrast, we report that the toxicity of ⌬105–125 and
Endocytosis is not required for toxicity
⌬32–134 PrPs is not dependent on endogenous GAGs, since inhibition of GAG sulfation using chlorate or enzymatic release of
PrP C is a GPI-anchored membrane protein that is constitutively
endocytosed via clathrin-coated pits and recycled back to the cell
surface GAG chains with heparinase does not affect toxic activity
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in the cell culture assay. Together, these
results suggest that exogenously applied
GAGs do not act by interrupting a functional interaction between PrP and endogenous GAGs. Rather, mutant PrP
toxicity may depend on binding to other,
non-GAG molecules on the cell surface
through the 23–31 region, perhaps via
electrostatic interactions involving positively charged residues. This interaction
may be competitively inhibited by supraphysiological levels of exogenous, negatively charged GAGs. A prediction from
the results presented here is that intracerebral administration of GAGs such as PS will
ameliorate neurodegeneration in Tg(⌬105–
125) or Tg(F35) mice. We are currently testing this possibility.
Possible mechanisms for involvement
of residues 23–31 in the toxicity of
mutant PrP and PrP Sc
How does the 23–31 region of PrP function in a cellular context to influence PrP
toxicity? We have recently found that expression in transfected cells of ⌬105–125
PrP induces large, spontaneous ionic currents that can be detected by patchclamping techniques (Solomon et al.,
2010b). These currents, which are produced by relatively nonselective, cationpermeable channels or pores in the cell
membrane, can be silenced by overexpression of wild-type PrP, paralleling the
ability of wild-type PrP to suppress the
neurodegenerative phenotype of Tg(⌬105–
125) mice. Similar currents are induced by
PrP molecules carrying several different
point mutations in the central region that
cause familial prion diseases in humans.
These results indicate that the neurotoxicity of some mutant forms of PrP is attributable to enhanced ion channel activity.
Interestingly, the ionic currents associ- Figure 9. GAGs suppress the toxicity of ⌬105–125 PrP in cell culture. A, HEK cells expressing WT or ⌬105–125 PrP were treated
ated with ⌬105–125 PrP can be rapidly for 48 h in the presence or absence of 400 g/ml G418, after which cell viability was measured by MTT reduction. Cell viability is
inhibited by treatment with PS (Solomon expressed as the value for MTT reduction (A570) of G418-treated cells as a percentage of the value for untreated cells. Where
et al., 2010b). In addition, we have found indicated, PS or heparin (each at 100 g/ml) were present during the 48 h incubation period. The bars show mean values ⫾ SEM.
that deletion of residues 23–31 abolishes The asterisks indicate values that are significantly different between PS- or heparin-treated cells compared with cells not treated
the current-inducing ability of ⌬105–125 with GAGs (p ⬍ 0.0001). B, HEK cells expressing WT or ⌬105–125 PrP were pretreated for 1 h in the presence of absence of heparin
PrP (Solomon et al., 2011). These results (“Hep”) (100 g/ml) or PS (100 g/ml), after which incubation was continued for an additional 30 min in the presence or absence
of Zeocin (400 g/ml). Cells were then lysed and analyzed for phosphorylated H2AX (␥-H2AX) and actin by Western blotting. The
suggest that exogenous GAGs block interpositions of ␥-H2AX, ubiquitinated ␥-H2AX (Ub-␥-H2AX), and actin are indicated. C, Western blot signals for ␥-H2AX were
actions of the 23–31 region of PrP with the quantitated and normalized to the amount of actin. ␥-H2AX levels in the presence of Zeocin were expressed as a fold change
membrane or with a cell surface receptor, relative to levels in the absence of Zeocin. A single experiment, representative of at least three similar ones, is shown.
and this interaction is essential for inducing current activity.
134, and other deleted forms of PrP involves the PTD activity of
It has been reported that residues 23–29 of PrP can function as
the N terminus, perhaps via formation of channels or pores in the
an autonomous “protein transduction domain” (PTD) that is
lipid bilayer.
capable of translocating polypeptides (either PrP itself or reporter
The results reported here may have relevance to the mechaproteins) across the lipid bilayer into the cytoplasm (Wadia et al.,
nisms by which PrP Sc elicits toxic effects during natural prion
2008). This process, which is thought to involve lipid raftdiseases. We have postulated that PrP Sc may activate some of the
mediated macropinocytosis, depends on an interaction of the
same neurotoxic signaling pathways as ⌬105–125 and other dePTD with cell surface GAGs, and can be inhibited by exogenous
leted forms of PrP (Li et al., 2007). If so, then residues 23–31 may
GAGs. Thus, it is possible that the toxicity of ⌬105–125, ⌬32–
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